Signaling by LRP5 mutants

Stable Identifier
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

LRP5 is subject to an in-frame missplicing event in breast and parathyroid cancers that renders the protein insensitive to inhibition by the WNT antagonist DKK1. Expression of the mutant protein results in elevated levels of active, unphosphorylated beta-catenin and enhanced TCF-dependent WNT-signaling, promoting cellular proliferation (Bjorklund et al 2007a, b; Bjorklund et al, 2009).

Literature References
PubMed ID Title Journal Year
19158955 The internally truncated LRP5 receptor presents a therapeutic target in breast cancer

Björklund, P, Akerström, G, Olsson, AK, Westin, G, Svedlund, J

PLoS ONE 2009
18044981 An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling

Björklund, P, Akerström, G, Westin, G

PLoS Med. 2007
17047023 Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors

Björklund, P, Akerström, G, Westin, G

J. Clin. Endocrinol. Metab. 2007
Name Identifier Synonyms
parathyroid carcinoma DOID:1540 malignant neoplasm of parathyroid gland, malignant neoplasm of the Parathyroid, parathyroid gland cancer, neoplasm of parathyroid gland, carcinoma of Parathyroid gland, Parathyroid gland neoplasm, malignant tumor of parathyroid gland (disorder), parathyroid neoplasm
breast cancer DOID:1612 malignant tumor of the breast, mammary cancer, malignant neoplasm of breast, mammary tumor, primary breast cancer, breast cancer, Ca breast - NOS, breast tumor
Cite Us!